Germany's Federal Institute for Drugs and Medical Devices (BfArM) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's (NYSE: NVO) popular diabetes medication, Ozempic, due to an ongoing scarcity.
Citing an interview with Spiegel magazine, Reuters noted BfArM President Karl Broich's concerns, emphasizing the escalating discussions with policymakers to address the drug shortage.
Broich underscored the possibility of enforcing export limitations if existing measures and public communications fail to alleviate the crisis, highlighting the imperative to retain adequate supplies within the ...